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Abstract
Background: To compare the efficacy and safety of budesonide/formoterol (Symbicort®) with
formoterol (Oxis®) in the treatment of patients with acute asthma who showed evidence of
refractoriness to short-acting β2-agonist therapy.
Methods: In a 3 hour, randomized, double-blind study, a total of 115 patients with acute asthma
(mean FEV1 40% of predicted normal) and a refractory response to salbutamol (mean reversibility
2% of predicted normal after inhalation of 400 µg), were randomized to receive either budesonide/
formoterol (320/9 µg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes [total dose
1280/36 µg]) or formoterol (9 µg, 2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes
[total dose 36 µg]). The primary efficacy variable was the average FEV1 from the first intake of study
medication to the measurement at 90 minutes. Secondary endpoints included changes in FEV1 at
other timepoints and change in respiratory rate at 180 minutes. Treatment success, treatment
failure and patient assessment of the effectiveness of the study medication were also measured.
Results: FEV1 increased after administration of the study medication in both treatment groups. No
statistically significant difference between the treatment groups was apparent for the primary
outcome variable, or for any of the other efficacy endpoints. There were no statistically significant
between-group differences for treatment success, treatment failure or patient assessment of
medication effectiveness. Both treatments were well tolerated.
Conclusion:  Budesonide/formoterol and formoterol provided similarly rapid relief of acute
bronchoconstriction in patients with asthma who showed evidence of refractoriness to a short-
acting β2-agonist.
Introduction
Patients presenting with symptoms of acute asthma are
traditionally treated with short-acting β2-agonists [1,2].
Formoterol is a long-acting β2-agonist with a rapid onset
of action, producing bronchodilation within 1–3 minutes
of inhalation [3-5]. This effect is comparable with that of
salbutamol [5], making formoterol suitable for the treat-
ment of acute asthma. In this setting, formoterol has
proved both safe and efficacious [6,7]. A large study per-
formed in an emergency room setting by Boonsawat and
colleagues [6] showed that high-dose formoterol was as
rapid and effective as high-dose salbutamol in reversing
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bronchoconstriction in patients with severe asthma, but
formoterol produced greater improvements than salbuta-
mol in lung function over 4 hours. For this reason, for-
moterol has been licensed for use as both maintenance
therapy and as an alternative to salbutamol and terbuta-
line for the relief of acute asthma symptoms.
Asthma patients experiencing acute symptoms may use
their β2-agonist reliever medication repeatedly. This can
result in downregulation of β2-receptors and consequent
relative refractoriness to the bronchodilatory effects of this
class of drug [8,9]. High doses of inhaled corticosteroid
(ICS) have been reported to upregulate these receptors
and restore β2-agonist responsiveness [10].
In order to study the potential of this favourable interac-
tion, Pansegrouw [11] examined the use of combined ICS
and short-acting β2-agonist treatment in patients with
acute asthma who initially showed no response to β2-ago-
nist therapy. It was reported that 'priming' patients with
ICS before commencing nebulised β2-agonist treatment
was more effective than therapy with the β2-agonist alone
at improving features of the exacerbation, including lung
function [11]. Although, to our knowledge, this study has
not been repeated, it raises the prospect that budesonide
and formoterol – which are now available together in a
combination inhaler (Symbicort®; budesonide/formot-
erol) – may be more effective than formoterol given alone
in treating patients with acute asthma who initially show
no response to β2-agonist therapy. The present study was
designed to compare the efficacy of budesonide/formot-
erol with that of formoterol for the treatment of patients
with acute asthma who had evidence of relative refractori-
ness to the administration of a short-acting β2-agonist.
Patients and methods
Patients
Patients aged ≥12 years presenting with acute asthma were
recruited from a total of 8 centres in Argentina, Mexico
and South Africa. All patients were required to have
asthma, as defined by the American Thoracic Society crite-
ria (including symptoms of wheeze, episodic cough, and
dyspnea) [12], with a pre-bronchodilator forced expira-
tory volume in 1 second (FEV1; measured on arrival in the
Table 1: Baseline demographics and clinical characteristics
Characteristic Formoterol (n = 57) Budesonide/formoterol (n = 58)
Male/female, n 20/37 22/36
Age, years (range) 43.9 (12–72) 45.9 (13–78)
Race, n (%)
Caucasian 39 (68) 37 (64)
Black 01  ( 2 )
Other 18 (32) 20 (34)
Asthma duration, years (range) 20 (1–65) 22.5 (0–54)
Acute severe asthma exacerbations in the 12 months before study entry
Number (%) of patients with event 56 (98) 54 (93)
Mean number of events (range) 6.3 (1–30) 6.4 (1–40)
Duration of current asthma exacerbation, n
<6 hours 22
6–12 hours 41
12–24 hours 41 1
>24 hours 47 43
FEV1, L (range) 1.15 (0.7–2.0) 1.12 (0.6–1.9)
FEV1, % of predicted normal (range) 41 (30–55) 40 (26–55)
Reversibility, % of predicted normal (range) 2.4 (-8 to +8) 2.1 (-7 to +8)
Reversibility, % of baseline (range) 5.8 (-18 to +23) 5.5 (-16 to +20)
Number (%) of patients prescribed long-acting β2-agonist at entry 4 (7) 6 (10)
Number (%) of patients prescribed ICS at entrya 16 (28) 17 (29)
ICS at entry, µg (range) 768 (160–2560) 624 (100–2400)
All values are presented as absolute numbers or as means, except asthma duration, for which the median is given. aDose of inhaled corticosteroid 
(budesonide equivalents) in patients receiving inhaled corticosteroid. FEV1 = forced expiratory volume in 1 second; ICS = inhaled corticosteroids.
Study design Figure 1
Study design.Respiratory Research 2006, 7:13 http://respiratory-research.com/content/7/1/13
Page 3 of 9
(page number not for citation purposes)
acute setting) ≥30% and ≤55% of predicted normal. In
addition, patients had to have a relative lack of reversibil-
ity, as demonstrated by their FEV1 improving by 8% or less
of predicted normal, 10 minutes after receiving salbuta-
mol 400 µg from a pressurised metered-dose inhaler.
Exclusion criteria included: acute severe asthma (defined
as an inability to generate an FEV1 value, an FEV1 of less
than 30% predicted, or asthma requiring transfer to an
intensive care unit on initial assessment); use of ICS
within the 8 hours preceding the baseline measurements;
receipt of oral or other systemic steroids in the 48 hours
before the baseline measurements; β-blocker therapy
(including eye drops); any significant disease or concom-
itant disorder; and known sensitivity to the study medica-
tion or lactose. Patients ≥45 years of age with a history of
≥10 pack-years of smoking were also excluded from the
study.
During the treatment period, patients were not permitted
to receive any asthma medication other than the investi-
gational product, although oxygen therapy was allowed.
Other medication considered necessary for the patient's
safety and well-being, and early withdrawal from the
study, were permitted at the discretion of the investigator.
Study design
This was a 180 minute, double-blind, double-dummy,
randomized, parallel-group multicentre study (Study
0693). The study was performed in accordance with the
ethical principles in the Declaration of Helsinki, Good
Clinical Practice guidelines, in addition to applicable
local regulatory requirements, and the protocol was
approved by local ethics review boards. Before any proce-
dure relating to the study was performed, written
informed consent was obtained from the patients and,
where applicable, from the patient's parent or legal guard-
ian.
The study design is shown in Figure 1. After the test of
response to salbutamol (Ventolin®, Glaxo Wellcome, UK;
100 or 200 µg [total dose 400 µg], administered using a
pressurised metered-dose inhaler with a Volumatic spacer
[Allen & Hanburys, UK]), eligible patients received either
budesonide/formoterol (Symbicort®  Turbuhaler®, Astra-
Zeneca, Sweden; 320/9 µg, 2 inhalations at t = -5 minutes
and a further 2 inhalations at t = 0 minutes [total dose
1280/36 µg], plus 2 inhalations of formoterol placebo
containing lactose at t = -5 minutes and at t = 0 minutes)
or formoterol (Oxis® Turbuhaler®, AstraZeneca, Sweden; 9
ug, 2 inhalations at t = -5 minutes and a further 2 inhala-
tions at t = 0 minutes [total dose 36 µg], plus 2 inhalations
of budesonide/formoterol placebo containing lactose at t
= -5 minutes and at t = 0 minutes). Oral prednisolone
(Approved Prescription Services, UK; 5 mg per tablet, 12
tablets [total dose 60 mg]) was administered to all
patients 90 minutes after they received the second dose of
study medication.
Efficacy assessments
The primary efficacy variable was the average FEV1 from
the first intake of study drug to the measurement at 90
minutes. The following were assessed as secondary effi-
cacy variables: the change in FEV1 at t = 3, 15, 60, 90 and
180 minutes after the last intake of study medication; the
change in respiratory rate at 180 minutes; the proportion
of patients with treatment success at 90 and 180 minutes;
the proportion of patients with treatment failure at 180
minutes; and the effectiveness of the study medication at
3 and 15 minutes.
FEV1 was measured by spirometry according to European
Respiratory Society (ERS) recommendations [13]. Respi-
ratory rate was counted for 1 minute at baseline (t = -15
minutes) and at 15, 30, 60, 90, 120, and 180 minutes after
the last intake of study medication. Treatment success was
judged by the investigator and defined in terms of a
patient being fit for immediate discharge at 90 and 180
Mean increase in FEV1 from baseline in patients treated with  either formoterol or budesonide/formoterol Figure 2
Mean increase in FEV1 from baseline in patients treated with 
either formoterol or budesonide/formoterol. At screening (t 
= -20 minutes), salbutamol 400 µg was administered to all 
patients to establish their relative refractoriness to β2-ago-
nist therapy. Patients in the formoterol group received for-
moterol 9 µg, 2 inhalations at t = -5 minutes and 2 inhalations 
at 0 minutes (total dose 36 µg). Patients treated with budes-
onide/formoterol received budesonide/formoterol 320/9 µg, 
2 inhalations at t = -5 minutes and 2 inhalations at 0 minutes 
(total dose 1280/36 µg). The timing of study drug administra-
tion is shown by vertical dotted lines on the figure. Patients 
received oral prednisolone 60 mg 90 minutes after the last 
administration of study drug.Respiratory Research 2006, 7:13 http://respiratory-research.com/content/7/1/13
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minutes. If treatment was considered successful at 90 min-
utes, the patient still remained in the study for the 180-
minute period. Treatment failure was defined as a require-
ment for additional asthma treatment and/or hospitaliza-
tion because of asthma during the timeframe of the study.
A subjective assessment of the effectiveness of the study
medication was determined by asking the patients
whether or not they considered the medication to be effec-
tive. An uncertain response was recorded as 'no'.
Safety assessments
The incidence, severity and type of adverse events occur-
ring during the study were recorded. Deterioration of
asthma was not recorded as an adverse event unless it
caused the patient to withdraw from the study or was
classed as serious by the investigator. A serious adverse
event was defined as an event that: caused death or was
immediately life-threatening; required inpatient care or
prolongation of hospitalization; resulted in persistent or
significant disability or incapacity; or required medical
intervention to prevent one of these outcomes.
Measurements of serum potassium, pulse rate, blood
pressure, electrocardiogram (ECG) variables, and oxygen
saturation were also used to assess safety. The outcome
variables for serum potassium were the minimum and
average values after administration. Blood samples for the
determination of this variable were obtained at baseline (t
= -15 minutes) and 30, 90 and 180 minutes after admin-
istration of the last dose of study medication.
Statistical methods
A sample size of 50 patients per group was required to
have an 80% chance of detecting a difference of 12%
between treatments in average FEV1 from the first intake of
study drug to the 90 minute measurement (5% signifi-
cance level, t-test, two-sided alternative hypothesis).
Efficacy analyses were performed on the full analysis set;
all patients who received at least one dose of study medi-
cation were included in the safety analysis. Changes in
FEV1 were analysed using multiplicative analysis of vari-
ance (ANOVA), with treatment and country as fixed fac-
tors and the pre-administration value (t = -5 minutes) as a
covariate. The change in respiratory rate was analysed
using additive ANOVA. The proportions of patients with
treatment success, treatment failure and reports of effec-
tive medication were analysed using logistic regression
models with treatment and country as factors. Odds ratios
were estimated and described with 95% confidence limits.
Clinical laboratory data, vital signs and physical measure-
ments relating to safety were compared between treat-
ment groups with an additive ANOVA model. Adverse-




Patients were enrolled and treated between April 2002
and August 2003. A total of 277 patients were recruited
into the study, 115 of whom fulfilled the inclusion criteria
and were randomized to receive treatment with either
budesonide/formoterol (n = 58) or formoterol (n = 57).
One patient, who was randomized into the formoterol
group, discontinued the study as a result of an adverse
event. The full analysis set comprised all randomized
patients.
The two treatment groups were comparable at baseline, in
terms of both demographics and other clinical character-
Table 2: Treatment comparisons (budesonide/formoterol vs formoterol) for all FEV1 outcome variables





Budesonide/formoterol vs formoterol: mean ratio, % (95% 
confidence limits)
p value
Eav 16.5 17.4 100.8 (96.1, 105.7) 0.74
Emax 26.3 27.2 100.7 (95.1, 106.7) 0.80
E3 13.3 14.1 100.7 (96.5, 105.1) 0.75
E15 15.8 16.4 100.5 (95.9, 105.3) 0.82
E60 17.2 18.6 101.2 (95.8, 106.9) 0.67
E90 18.2 19.7 101.3 (95.5, 107.3) 0.67
E180 16.5 16.5 100.0 (93.7, 106.7) 1.0
aBased on adjusted ratios from an analysis of variance model.
Eav is the average FEV1 (area under the curve) from the first intake of study drug (-5 minutes) to the +90-minute measurement (primary outcome 
variable). Emax is the change in FEV1 from pre-administration to the maximal value after administration. E3, E15, E60, E90 and E180 are the changes in 
FEV1 from pre-administration to 3, 15, 60, 90 and 180 minutes after the last administration of the study drug, respectively.
FEV1 = forced expiratory volume in 1 second.Respiratory Research 2006, 7:13 http://respiratory-research.com/content/7/1/13
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istics (Table 1). Patients reported a background of chronic
severe asthma of longstanding duration (median 21
years). In the year before entry into the trial, 96% of the
patients had experienced an exacerbation, with a mean
number of 6 events per patient per year. Despite this, only
29% of the patients reported using preventative ICS. At
study entry, the mean FEV1 was 1.13 L (40% of the pre-
dicted normal value). After treatment with salbutamol
400 µg, the mean reversibility in FEV1 was 5.6% of the
baseline value (2.2% of predicted normal).
Efficacy
Lung function
FEV1 increased after study drug administration in both
treatment groups (Figure 2). The average increase from
baseline in FEV1 (area under the curve) from the first
intake of study drug to the 90-minute measurement was
17.4% in patients receiving budesonide/formoterol and
16.5% in formoterol-treated patients. There was no signif-
icant difference between the groups for the primary out-
come variable.
There were no statistically significant differences between
the budesonide/formoterol and formoterol treatment
groups with regard to either the change in FEV1 at any of
the timepoints analysed over the full 180-minute assess-
ment period, or for the maximal FEV1 value achieved
(Table 2).
Respiratory rate
The respiratory rate decreased over time in both treatment
groups (Figure 3), with no statistically significant
between-group difference being apparent. In patients
receiving budesonide/formoterol, the mean pre-dose
value (breaths per minute) was 23.5, decreasing to 19.2 at
t = 180 minutes. The corresponding values for the formot-
erol group were 22.6 and 18.4, respectively.
Treatment success, treatment failure and effectiveness of medication
There was a slight numerical advantage in the percentage
of patients reporting treatment success in the budesonide/
formoterol group (79% and 90% at 90 and 180 minutes,
respectively) compared with those being treated with for-
moterol (74% and 84% at 90 and 180 minutes, respec-
tively). Despite the initially poor response to salbutamol
in all patients, only a small minority of treatment failures
were seen in both groups (10% and 16% for patients
treated with budesonide/formoterol and formoterol,
respectively). The majority of patients described their
medication as effective. After 3 minutes, 97% of patients
receiving budesonide/formoterol considered their medi-
cation to be effective; this figure remained at 97% at 15
minutes. The corresponding values for the formoterol
treatment group were 93% and 96%, respectively.
There were no statistically significant between-group dif-
ferences for any of these variables.
Safety
Adverse events
Nine patients in each treatment group (16%) reported a
total of 24 adverse events. There were 13 adverse events in
patients receiving budesonide/formoterol and 11 in the
formoterol treatment group. These events were mostly
mild or moderate in intensity. Tremor and headache were
the most frequently reported adverse events and there
were no differences between the treatment groups in the
incidence of patients reporting these symptoms (Table 3).
One patient in the formoterol group discontinued the
study after 2 hours because of worsening asthma. A
patient in the budesonide/formoterol group suffered a
serious deterioration in asthma symptoms but managed
to complete the study. These two episodes were reported
as serious adverse events (asthma aggravated). Neither
was considered to be causally related to the study drug.
There were no deaths during the study.
Clinical laboratory data and other safety evaluations
Treatment with both budesonide/formoterol and formot-
erol was well tolerated and systemic effects were similar
for both treatments. The majority of patients in both treat-
ment groups had normal serum potassium before treat-
ment and at the end of the study period. The mean values
for the average serum potassium during the 180 minutes
after study drug administration were 3.82 and 3.88
mmol/L for the budesonide/formoterol and formoterol
groups, respectively. The corresponding mean pre-dose
values were 3.83 and 4.01 mmol/L, respectively. Abnor-
mally low values (<3.0 mmol/L) were reported for two
patients 180 minutes after the last intake of study medica-
tion; both of these patients were in the formoterol group.
The lowest treatment value recorded for a patient in the
budesonide/formoterol group was a transient decrease to
2.7 mmol/L after 90 minutes; the lowest value for formot-
erol-treated patients was 2.6 mmol/L, which occurred in a
patient with a pre-dose value of 2.4 mmol/L. In the for-
moterol group, one case of hypokalaemia was reported as
an adverse event. Overall, the effects of budesonide/for-
moterol and formoterol on serum potassium were small
and were not considered to be clinically important; there
were no statistically significant differences between the
treatment groups with regard to this parameter.
Vital signs, ECG parameters and oxygen saturation also
showed only small changes over time during the course of
the study. There were no statistically significant differ-
ences between the treatments for the average or maxi-
mum/minimum values for any of these variables, with the
exception of heart rate, for which budesonide/formoterolRespiratory Research 2006, 7:13 http://respiratory-research.com/content/7/1/13
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had a lower maximum value (mean of 91.6 beats per
minute) than formoterol (mean of 94.3 beats per minute;
p = 0.026).
Discussion
Patients with acute asthma require efficacious medication
to reduce bronchoconstriction. In this study, budesonide/
formoterol and formoterol proved similarly safe and
effective for the treatment of patients with acute asthma
who had not initially responded adequately to the short-
acting  β2-agonist, salbutamol. There was no difference
between the two treatments with regard to their efficacy
and tolerability over the 180-minute assessment period.
At the end of the study, a high proportion of patients in
both groups had been successfully treated.
Previous studies have demonstrated that formoterol is at
least as effective as salbutamol for the treatment of acute
exacerbations [7,6] and its role in providing as-needed
relief from symptoms has been well demonstrated
[14,15]. The similar efficacy of budesonide/formoterol
and formoterol seen in our patient population suggests
that budesonide/formoterol can also be used for as-
needed symptom relief in patients with acute severe bron-
chospasm. Further evidence to support this has been
obtained by Balanag and colleagues [16] who demon-
strated that budesonide/formoterol and salbutamol had
similar short-term efficacy in relieving acute asthma exac-
erbations. However, unlike the Balanag study, we enrolled
patients with acute asthma who demonstrated initial
refractoriness to salbutamol. We were, however, unable to
demonstrate evidence of an enhanced β2-receptor
response in patients receiving therapy with ICS, as has
been described previously [10,11,17]. A possible reason
for our results is that, despite our patients' poor response
to salbutamol 400 µg (mean improvement in FEV1 of only
5.6% from baseline), they may not have been sufficiently
refractory to demonstrate the potential benefit provided
by ICS. This is suggested by the rather good initial
responses (additional improvements in FEV1 of 13.3%
and 18.2% at 3 minutes and 90 minutes after dosing,
respectively) in the patients who received formoterol
alone.
The identification of patients with refractoriness to β2-
agonists in acute asthma is complicated by both concep-
tual and methodological problems. Among the former are
the difficulty in distinguishing between β2-agonist refrac-
toriness caused by downregulation – a feature that has
been confirmed in vitro [8], but not in vivo – and a lack of
clinical response caused by pathological changes in asth-
matic airways (e.g. mucus plugging, oedema of the bron-
chial wall) and chronic structural changes (such as airway
remodelling) [18,19]. Assays of β2-agonist receptor den-
sity on circulating monocytes, together with other in vitro
tests, may have been useful, but the results of such testing
would not have been available in time to assist with
patient selection for this acute study. A minority of
patients were being treated with ICS at the time of their
exacerbation, but most had a history of previous exacerba-
tions, suggesting that many patients' asthma had been
chronically undertreated. In addition, for 78% of the
patients the acute symptoms had lasted for >24 h before
study entry and so it is possible that, in many patients, air-
way pathology may have been well established. Conse-
quently, airway pathology, rather than downregulation of
β2-agonist receptors, may have accounted for β2-agonist
refractoriness.
Another challenge when selecting patients for a study such
as the one we have reported here, is to establish accurately
patients' prior dosing with β2-agonists. Patient recall of β2-
agonist use is often poor. Moreover, we waited only 15
minutes after administering salbutamol 400 µg before
patients were treated with the study drug. This was neces-
sary because patients were distressed and it was consid-
ered neither safe nor compassionate to await the peak
effect of the salbutamol (between 15 and 30 minutes after
Change in respiratory rate in patients treated with formot- erol or budesonide/formoterol Figure 3
Change in respiratory rate in patients treated with formot-
erol or budesonide/formoterol. At screening (t = -20 min-
utes), salbutamol 400 µg was administered to all patients to 
establish their relative refractoriness to β2-agonist therapy. 
Patients in the formoterol group received formoterol 9 µg, 2 
inhalations at t = -5 minutes and 2 inhalations at 0 minutes 
(total dose 36 µg). Patients treated with budesonide/formot-
erol received budesonide/formoterol 320/9 µg, 2 inhalations 
at t = -5 minutes and 2 inhalations at 0 minutes (total dose 
1280/36 µg). The timing of study drug administration is 
shown by vertical dotted lines on the figure. Patients 
received oral prednisolone 60 mg 90 minutes after the last 
administration of study drug.Respiratory Research 2006, 7:13 http://respiratory-research.com/content/7/1/13
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administration) to exclude patients who responded more
slowly. In contrast, patients were followed for longer peri-
ods after receiving the study drugs. There was, however,
some evidence that the initial response to salbutamol was
already at a plateau or in decline when the study drugs
were administered, although there was no evidence of a
loss of effect with either of the study drugs during the 3-
hour assessment (Figure 2).
Differences in methods of patient selection may have
accounted for the differences between our results and
those reported with early ICS dosing in previous trials
[10,11,17]. However, it should be noted that Pansegrouw
[11] provided little detail from which to gauge his
patients' prior treatment or degree of refractoriness to β2-
agonists, although the patients in that study had asthma
of a similar severity to the patients enrolled into our study.
There are other possible reasons for a lack of additional
benefit with ICS. For instance, if patients had received pre-
vious treatment with corticosteroids, there might have
been a carry-over of the effect of this medication.
Although patients were not permitted to receive ICS
within the 8 hours before the baseline measurements, or
oral/systemic steroids in the 48 hours before the baseline
measurements, a protective effect of prior dosing may still
have been apparent. However, as only 29% of the patients
were using ICS on study entry, this may not account for
the lack of additional benefit seen with budesonide/for-
moterol compared with formoterol in this study. The early
response to ICS may depend on the repeated administra-
tion of high doses of the drug, as postulated by Rodrigo
and Rodrigo [17]. In their study, patients with acute
asthma of more than 24 hours' duration had a signifi-
cantly better response when treated with high cumulative
doses of flunisolide in addition to salbutamol than those
treated with salbutamol alone. Patients in our study
received only two doses of budesonide/formoterol, which
may not have been sufficient for a meaningful topical
response. Finally, there are limitations to using spirometry
alone in determining nonresponsiveness to β-agonists.
Pansegrouw [11] is not alone in demonstrating the effect
of ICS in refractory asthma. Aziz and Lipworth [10]
reported that a bolus of inhaled budesonide (1600 µg)
rapidly reversed formoterol subsensitivity to adenosine
monophosphate bronchoprotection in patients with
asthma who were receiving regular formoterol. Addition-
ally, other mechanisms of action of ICS in acute asthma
have been proposed. Engel and colleagues [20] demon-
strated improvements in lung function over 3 hours with
budesonide administered alone (i.e. in the absence of β2-
agonists) versus placebo. While an improvement in lung
function was evident 1 hour after drug administration, the
effects increased over time to become statistically signifi-
cantly different compared with placebo at 3–4 hours [20].
In the present study, efficacy data were collected over a
180-minute time period. Measurements extending
beyond this timeframe may have proved valuable in
assessing the contribution of budesonide to improving
lung function. However, for ethical reasons all patients
were treated with oral prednisolone 90 minutes after
receiving the last dose of study medication, and this may
have limited the utility of observations continuing for
longer than 3 hours.
It is also possible that the dose of budesonide used in this
study was too low. In patients who deteriorate whilst on
regular doses of ICS, doubling the maintenance dose
when symptoms of an exacerbation become apparent has
not been shown to be effective in preventing the exacerba-
tion [21,22], but a fourfold increase in dose at the onset
of an exacerbation may be beneficial [23]. These studies
[21-23] examined the effects of treatment on patients over
weeks and months; the study that we describe here
assessed the efficacy of treating exacerbations over a 180-
minute time period. Studies involving budesonide/for-
moterol for maintenance and reliever therapy have shown
Table 3: Most commonly reported adverse events in patients treated with formoterol or budesonide/formoterol
Preferred term Formoterol (n = 57) Budesonide/formoterol (n = 58)
Tremor 4 (7) 4 (7)
Headache 3 (5) 3 (5)
Asthma aggravated 1 (2) 1 (2)
Tachycardia 2 (4) 0
AE associated with test procedure 0 1 (2)
T-wave changes 0 1 (2)
Chest pain 0 1 (2)
Hypokalaemia 1 (2) 0
Dizziness 0 1 (2)
Pruritus 0 1 (2)
The number (%) of patients with each adverse event is given.
AE = adverse event.Respiratory Research 2006, 7:13 http://respiratory-research.com/content/7/1/13
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that timely increases in the budesonide/formoterol dose
as the symptoms of loss of control of asthma become
apparent can result in a marked reduction in exacerba-
tions [24,25]. These results suggest that treatment with an
ICS and long-acting β2-agonist combination (at the dose
administered in the present study) is effective in prevent-
ing severe exacerbations if given very early, when the
symptoms of loss of asthma control first become appar-
ent, but may be less beneficial for patients in whom an
exacerbation has become established. In our study inves-
tigating symptom relief in patients with acute asthma, the
long-acting β2-agonist alone was as effective as the combi-
nation therapy – even in patients presenting for emer-
gency treatment who had used their short-acting β2-
agonist liberally and appeared to be refractory to β2-ago-
nist therapy, as judged by poor bronchodilatory response
to short-acting β2-agonists.
In addition to being effective, both budesonide/formot-
erol and formoterol were safe and well tolerated in the
present study. The patterns of adverse events raised no
safety concerns and, overall, the changes over time in sys-
temic effects were very minor. These results are in line
with those from earlier studies. Ankerst and colleagues
[26] have reported systemic effects associated with the
administration of budesonide/formoterol to be small,
and the systemic effects of formoterol have generally been
reported as minor and similar to salbutamol [6,7,16,27].
In conclusion, budesonide/formoterol and formoterol
provide rapid relief of acute bronchoconstriction in
patients with asthma, producing effects of a similar mag-
nitude. Both preparations are well tolerated.
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